Garry A. Neil, M.D.
Dr. Neil joined the Board of Directors in August 2016 and currently serves as a member of both the Nominating & Governance Committee and the Scientific and Development Committee. Dr. Neil is currently the Chief Scientific Officer at Aevi Genomic Medicine, a company focused on treating patients with rare genetic and orphan diseases. Prior to joining Aevi Genomic Medicine in 2013, Dr. Neil was a Partner and the Head of R&D at Apple Tree Partners, a life sciences private equity firm. From 2002 to 2012, Dr. Neil held various leadership positions including Corporate Vice President of Science & Technology at Johnson & Johnson, and Group President at Johnson & Johnson Pharmaceutical Research and Development. Prior to joining Johnson & Johnson, he held senior positions at Astra Merck, AstraZeneca, and EMD Pharmaceuticals. Under his leadership several important medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases gained initial or expanded approvals.
Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. He completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He held faculty positions at the Ludwig Institute for Cancer Research, the University of Iowa and the University of Pennsylvania (adjunct).
Dr. Neil serves on the Boards of Reagan-Udall Foundation and the Foundation for the U.S. National Institutes of Health (NIH), and is a past member of the Science Management Review Board of the NIH. He is past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee, the PhRMA Foundation Board and he is the founding Chairman of TransCelerate BioPharma, Inc.